Zobrazeno 1 - 10
of 246
pro vyhledávání: '"G A Omura"'
Autor:
Lesley A. Stewart, S. B. Kaye, S. Pecorelli, N. Colombo, C. Mangioni, R. V. Smalley, B. Y. Yeap, D. W. Wilbur, R. C. Leonard, M. F. Brady, E. Wiltshaw, P. F. Conte, S. Marsoni, J. F.G. Sturgeon, M. H.N. Tattersall, C. Gennatas, C. Trope, A. Athanazziou, D. Guthrie, D. Crowther, D. R. Bell, A. H. Laing, M. Gore, J. B. Vermorken, C. Lewis, E. Gilbey, Giorgio Bolis, H. Bruckner, P. Adnitt, M. K.B. Parmar, M. Tomirotti, H. Meerpohl, H. S. Brodovsky, W. Sauerbrei, J. Pater, R. Canetta, W.W. ten Bokkel Huinink, D. V. Skarlos, H. J. Solomon, M. J. Webb, J. T. Wharton, F. Landoni, P. Y. Liu, M. M. Turbow, J. H. Edmonson, D. S. Alberts, C. J. Cohen, K. Aabo, W. Torri, V. Barley, M. Adams, M. Buyse, C. J. Williams, M. Presti, V. Chylak, U. Bianchi, G. A. Omura
Publikováno v:
Scopus-Elsevier
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the
Autor:
D. C. Ihde, A. M. Fremgen, J. M. Cain, D. Lowy, M. R. Henry, A. H. Epstein, B. L. Andersen, J. R. Lunney, P. W. Grigsby, D. K. Ash, J. Ruffin, M. H N Tattersall, M. F. Mitchell, H. W. Lawson, Frederick Stehman, R. C. Park, C. McNeil, P. J. Hitchcock, B. S. Kramer, J. F. Magrina, J. M. Elliott, M. A. Penalver, W J Jr Spanos, A. S. Lichter, R. S. Berkowitz, R. M. Lanciano, P. E. Saigo, J. H. Ferguson, I. Gage, M. A. Steller, C. Nichols, P. S. Braly, Carol L. Brown, C. P. Hunter, R. L. Sweet, J. L. Bader, M. E. Randall, K. D. Hatch, W. H. Hall, V. W. Pinn, J. Overgaard, G L Sr Eddy, A. H. Rusell, D. Kapp, G. A. Omura, A. E. Howes, M. Morris, D. G. Petereit, J. A. Benda, J. S. Hutchison, P. J. Eifel, A. F. Saftlas, R. Herrero, H. M. Keys, S. Scherr, N. Munoz, G. M. Thomas
Publikováno v:
Gynecologic Oncology. 66:351-361
Autor:
N L, Bartlett, G R, Petroni, B A, Parker, N D, Wagner, J P, Gockerman, G A, Omura, G P, Canellos, M, Robert, J L, Johnson, B A, Peterson
Publikováno v:
Cancer. 92(2)
To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluati
Autor:
G A, Omura
Publikováno v:
Journal of the National Cancer Institute. Monographs. (21)
Numerous drugs and drug combinations have been evaluated, largely in phase II trials, for the treatment of carcinoma of the uterine cervix. There clearly is a need for effective chemotherapy for this disease, but the results to date have unfortunatel
Publikováno v:
Leukemia. 9(9)
A phase III clinical trial was designed to determine if more intensive induction and consolidation therapy for acute myeloblastic leukemia increases the remission rate and prolongs survival. A minor objective was to determine if the use of non-cross
Publikováno v:
Leukemia. 8(11)
A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelog
Autor:
R J, Mayer, R B, Davis, C A, Schiffer, D T, Berg, B L, Powell, P, Schulman, G A, Omura, J O, Moore, O R, McIntyre, E, Frei
Publikováno v:
The New England journal of medicine. 331(14)
About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission therapy i
Autor:
G A, Omura
Publikováno v:
Seminars in oncology. 21(1)
Autor:
G A, Omura
Publikováno v:
Oncology (Williston Park, N.Y.). 6(4)
There clearly is a need for effective chemotherapy for early-stage, high-risk patients with carcinoma of the uterine cervix, and for those with advanced disease. Results to date have been disappointing. Cisplatin is active but overrated. Ifosfamide a
Publikováno v:
American journal of clinical oncology. 14(4)
In a multicenter trial, we evaluated the antiemetic efficacy of ondansetron, a selective serotonin type 3 (5-HT3) receptor antagonist, in 42 adult chemotherapy-naïve patients receiving a multiple-day cisplatin regimen (20-40 mg/m2 per day for 4-5 da